Tema Neuroscience and Mental Health ETF Rating $21.48 +0.38 (+1.80%) Closing price 04/17/2025 03:41 PM EasternExtended Trading$21.48 0.00 (0.00%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock Tema Neuroscience and Mental Health ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.MNTL Aggregate RatingModerate Buy 2.81Holdings in MNTL have an aggregate rating of Moderate Buy based on 585 analyst ratings issued in the past year covering 39 companies (91.0% of the portfolio).MNTL Aggregate Price Target$21.48High Prediction$21.48Average Prediction$21.48Low Prediction$21.48Holdings in MNTL have an aggregate price target of $21.48 and a range of $21.48 to $21.48 covering 39 companies (91.0% of the portfolio).MNTL Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy14 Buy rating(s)Moderate Buy23 Moderate Buy rating(s)Hold2 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Neuroscience and Mental Health ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 39 MNTL Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings12.24%VRTXVertex Pharmaceuticals$489.10+0.7%4.1092 of 5 stars2.64$512.41 4.8%25Short Interest ↓News CoveragePositive News8.06%REGNRegeneron Pharmaceuticals$563.16+2.5%4.84 of 5 stars2.77$963.56 71.1%26Analyst ForecastNews CoveragePositive News5.51%ARGXargenx$596.20+1.5%3.2983 of 5 stars2.91$699.28 17.3%23Analyst ForecastNews Coverage5.01%ALNYAlnylam Pharmaceuticals$234.56+1.8%4.63 of 5 stars2.77$315.58 34.5%26Analyst RevisionNews CoveragePositive News4.48%LLYEli Lilly and Company$841.70+14.5%4.7943 of 5 stars2.89$1,012.00 20.2%19News CoveragePositive NewsGap UpHigh Trading Volume4.42%TEVATeva Pharmaceutical Industries$13.61+1.3%3.083 of 5 stars2.86$23.43 72.2%7Positive News3.85%NBIXNeurocrine Biosciences$101.38+1.3%4.882 of 5 stars2.91$161.86 59.7%23Analyst UpgradeAnalyst RevisionPositive NewsGap Up3.77%CRNXCrinetics Pharmaceuticals$30.42+2.8%3.5045 of 5 stars2.92$73.00 140.0%13Positive News3.22%BIIBBiogen$118.61+2.9%4.677 of 5 stars2.42$213.15 79.7%31Upcoming EarningsAnalyst ForecastAnalyst Revision3.04%SYKStryker$346.46-0.1%4.6713 of 5 stars2.79$423.53 22.2%19News CoveragePositive News2.75%MDTMedtronic$82.58-0.1%4.7176 of 5 stars2.44$96.14 16.4%16Short Interest ↓News CoveragePositive News2.74%CPRXCatalyst Pharmaceuticals$22.52+1.5%4.5995 of 5 stars3.13$32.29 43.4%8News CoveragePositive News2.56%AXSMAxsome Therapeutics$104.460.0%4.58 of 5 stars3.00$169.80 62.6%16Analyst RevisionPositive News2.39%IONSIonis Pharmaceuticals$28.40+0.2%4.0398 of 5 stars2.70$56.72 99.7%20Analyst ForecastAnalyst RevisionNews Coverage1.96%DNLIDenali Therapeutics$12.74+1.5%4.0114 of 5 stars3.00$37.57 194.9%171.95%XENEXenon Pharmaceuticals$35.14+4.0%2.7354 of 5 stars3.00$56.78 61.6%10Analyst DowngradeOptions VolumeAnalyst RevisionNews Coverage1.94%JAZZJazz Pharmaceuticals$102.78+1.2%4.8892 of 5 stars2.93$187.71 82.6%14News CoveragePositive News1.89%ALKSAlkermes$27.05-0.5%4.6944 of 5 stars2.67$38.50 42.3%12Short Interest ↓Analyst Revision1.84%OPCHOption Care Health$32.09-0.6%3.154 of 5 stars2.75$33.00 2.9%8Short Interest ↑News CoveragePositive News1.78%PENPenumbra$276.62-0.4%4.0498 of 5 stars2.88$293.93 6.3%17Upcoming EarningsAnalyst ForecastInsider TradeShort Interest ↑News CoverageGap Up1.68%ACADACADIA Pharmaceuticals$14.73+1.1%4.0203 of 5 stars2.50$23.93 62.5%16Analyst RevisionNews CoveragePositive News1.53%DXCMDexCom$68.59-0.2%4.9044 of 5 stars2.95$99.00 44.3%20News CoveragePositive News1.46%RNAAvidity Biosciences$26.66+3.5%2.1795 of 5 stars3.00$66.69 150.2%13Positive News1.40%PTCTPTC Therapeutics$47.39+2.1%3.8673 of 5 stars2.53$63.77 34.6%15Upcoming EarningsShort Interest ↑News Coverage1.33%SRRKScholar Rock$30.71+3.2%3.8847 of 5 stars3.00$42.67 39.0%6News CoveragePositive News1.08%SRPTSarepta Therapeutics$53.79-0.3%4.5647 of 5 stars2.83$161.83 200.8%24Positive NewsGap Down0.88%IMVTImmunovant$15.15+2.1%2.2241 of 5 stars3.00$41.00 170.6%10Insider TradeShort Interest ↑0.86%DAWNDay One Biopharmaceuticals$6.84+1.2%2.7052 of 5 stars3.13$32.29 372.0%8Positive News0.85%TALKTalkspace$2.67-2.2%3.9476 of 5 stars3.00$4.50 68.5%7News CoveragePositive News0.79%ACHCAcadia Healthcare$23.91+0.3%4.5177 of 5 stars2.67$50.39 110.7%9High Trading Volume0.75%PRTAProthena$9.20-0.6%3.1702 of 5 stars2.75$55.00 497.8%8News CoveragePositive News0.71%BHVNBiohaven$20.41+9.2%3.6537 of 5 stars3.07$62.77 207.6%15Analyst Revision0.54%NTLAIntellia Therapeutics$7.23+5.4%4.3352 of 5 stars2.63$37.56 419.4%190.48%VYGRVoyager Therapeutics$3.16+1.0%4.4322 of 5 stars3.11$13.97 342.0%9Analyst Revision0.36%DYNDyne Therapeutics$8.17+4.3%3.4967 of 5 stars3.07$47.46 480.9%150.34%PRAXPraxis Precision Medicines$33.79+13.3%3.1151 of 5 stars2.78$123.33 265.0%9News CoveragePositive NewsGap Up0.26%SLDBSolid Biosciences$2.55+1.2%3.435 of 5 stars3.33$15.67 514.4%12Positive News0.15%RAPPRapport Therapeutics$10.15+4.0%1.6635 of 5 stars3.00$32.67 221.8%4Short Interest ↑News Coverage0.14%ARVNArvinas$8.60+12.4%3.622 of 5 stars2.69$34.33 299.2%16Analyst ForecastShort Interest ↓News CoveragePositive NewsHigh Trading Volume This page (NASDAQ:MNTL) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Neuroscience and Mental Health ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Neuroscience and Mental Health ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
